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摘   要  
帕金森病是继老年痴呆症之后世界第二大威胁人类健康的神经退行性疾病，











1.VIP 体外方法学的建立和稳定性考察。利用高效液相色谱法对 VIP 的含量
进行测定，研究了 VIP 多肽的稳定性。结果表明：VIP 在 -80 ℃下保存最稳定，
至少可保存一个月不降解，故该药制成制剂宜冷冻保存。在室温（ ~ 25 ℃）范
围内、pH 值 2.0 ~ 7.0 之间以及搅拌速度为 800 ~ 1000 rpm 搅拌 4 h的条件下，
制备成的纳米粒不会影响 VIP 的稳定性。 
2.纳米粒的制备。采用改良的乳化聚合法制备纳米粒，对表面活性剂的种类
和用量、载体材料的用量、药物与材料比例、pH 值等进行单因素实验考察；采
用正交设计优化处方，确定最佳处方，得到粒径为 147.7 nm，包封率为 95.3 %，
载药量为 4.77 %的聚山梨酯-80（Polysorbate 80，P80）修饰的 VIP 纳米粒。同时



















凋亡能力，并显著改善了 6-OHDA 诱导的 SH-SY5Y 细胞线粒体膜电位。说明聚
山梨酯-80 修饰的 VIP 纳米粒提高了 VIP 的稳定性和被细胞摄取能力，与 VIP 溶
液相比有更强的体外神经保护活性。因此聚山梨酯-80 修饰的 VIP 纳米粒可能具
有更好的预防帕金森病的潜力。 















Parkinson’s disease (PD) is the second most common neurodegenerative disorder, 
after Alzheimer’s disease. It has affected about 1 ~ 2 % of the population over the age 
of 60 years seriously. The development of Biomedical Technology has contributed to 
the discoveries of peptides and proteins with considerable potential in the treatment of 
central nervous system (CNS) diseases (such as Parkinson’s disease and Alzheimer’s 
disease). However, a significant challenge to their clinical administration and  
treatment is their ideal drug delivery to the CNS crossing the blood-brain barrier 
(BBB). New drug delivery system of peptides and proteins is necessary and full of 
esperance for both the Pharmacy research and the social meaning. 
Vasoactive intestinal peptide (VIP), as a important regulatory neuropeptide, has 
been proposed as a therapeutic drug candidate for the treatment of Parkinson’s disease  
and Alzheimer’s disease. However, like most endogenic peptides, its potential thera- 
peutic applications are limited by its its rapid elimination after intravenous admini-  
stration and poor passage across the BBB. The aim of the current study was to investi-  
gate the VIP loading nanoparticles and its neuroprotective effect in vitro.  
The following parts are included in this paper: 
1. The study on analysis method in vitro and stability of VIP. By using high 
performance liquid chromatography (HPLC) method, we studied the effect of di- 
fferent factor upon VIP under the preparation condition.  The optimum maintaining 
condition is to be preserved by -80 ºC. And the rotation speed of 800 ~ 1200 
revolutions per minute for 4 hours at room temperature and pH value 2.0 ~ 7.0 is safe 
for the preparation. The experiment indicates that VIP is stable enough to survive 
through the whole preparation process. 
2. Preparation of nanoparticles. Nanoparticles was prepared by modified emul-  
sion polymorization method. The factors in the formulations such as different species 
and concentration of surfactant, the ratio of drug and polymer, the pH value and so on 
were tested, the formulation was further optimized by orthogonal experiment. We use 
the best kind of method to obtain Polysorbate 80-VIP-NP, which diameter is 147.7 nm, 
ER is 95.2 % and DR is 4.77 %. At the same time, we prepare Polysorbate 80- 
FITC-NP, which can be uptaken by SH-SY5Y cell, and make contribution to the 














3. Study on pharmacodynamics of VIP nanoparticles in vitro. The cell model of 
PD have been established successfully by inducing SH-SY5Y apoptosis wih 6-OHDA. 
Polysorbate 80 modified nanoparticles showed no effect on cell viability, indicating 
that they have no role in cell survival. In vitro cell culture study showed enhanced cell 
viability of Polysorbate 80-VIP-NP against 6-OHDA induced cytotoxicity in SH- 
SY5Y neuroblastoma cells compared to VIP solution. Polysorbate 80-VIP-NP 
increased the antiapoptosis activity and restored the loss of mitochondrial membrane 
potential (MMP) significantly compared to VIP solution. From all the experiments, it 
was found that the activity of VIP was enhanced with Polysorbate 80 modified PBCA 
nanoparticles compared to VIP solution suggesting enhanced stability and cell up- 
take. These results suggest that Polysorbate 80-VIP-NP has more protective effects 
against 6-OHDA induced apoptosis,which might be a potential therapeutic agent for 
preventing Parkinson’s disease. 
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